POLYPHARMACY IN ELDERLY PATIENTS:
AN INTERVENTION STUDY IN THERAPEUTIC
MANAGEMENT
Rosario Falanga¹, G. Pessa¹, B. Basso²,
A. Bertoli², A. Franzo², D. Little², G. Simon²
¹General Practitioner, SIMG, Pordenone, Italy,
²Azienda per l’Assistenza Sanitaria n.5 “Friuli Occidentale”,
Pordenone, Italy
Background
 The increase in average life expectancy has over time
resulted in a rising incidence of chronic degenerative
diseases and consequent polypharmacy in older adults,
with an augmented risk of Adverse Drug Reactions
(ADRs) and Potentially Inappropriate Drug Prescriptions
(PIDP).
 Older people are medically frail because of age-
related pharmacokinetic and pharmacodynamic
changes.
 Deprescribing will reduce the risk of adverse drug
reactions due to age-related physiological changes and
inappropriate prescriptions.
PERCENTAGE OF REPORTS WITH POTENTIAL DRUG-DRUG
INTERACTIONS IN RELATION TO THE NUMBER OF DRUGS
IDENTIFYING ADVERSE DRUG REACTIONS ASSOCIATED WITH DRUG-DRUG
INTERACTIONS DATA OF A SPONTANEOUS REPORTING DATABASE IN ITALY (Leone R.,
Drug Saf 2010)
Ippocrate (460 - 335 B.C.)
“PRIMUM NON NOCERE”
(First, do not harm)
Polypharmacy in elderly patients: an intervention
study in therapeutic management
 Pharmacovigilance project financed by the Italian
Medicines Agency (AIFA).
 Participating Organisations and Facilities:
 AAS5 “Agency for Public Health Service n.5
Western Friuli” (Office of the Medical Director,
Internal Medicine Department, Pharmacy
Department, Territorial Health Districts, Dept. of
Mental Health, Nursing Services)
 General Practitioners (SIMG, Pordenone)
 Nursing homes in the Province of Pordenone
Objectives
 We conducted a qualitative and quantitative
analysis of polypharmacy in elderly patients, in
therapy with multiple prescription medicines
evaluating the risk of ADRs, drug interactions
and therapeutic errors before and after
adequate staff training aimed at reducing the
number of administered drugs and ADRs in this
population.
Methods (1)
A cohort of 750 elderly
patients living in 11
nursing homes, in the
province of Pordenone in
northern Italy, average
age 85 (65-103), 81%
females, were enrolled
in the study, which lasted
for 3 years (2013-2015)
and included 3 phases.
Age Phase 1
n.1123
Phase 2
Training
Phase 3
n.1112
Present
Both
phases
n.750
Min. 65 65 65
Max 106 103 103
Media 86 85 85
Female% 79 79 81
Methods (2)
 Phase 1: included medical record audit, data collection of
drug therapy and drug management, evaluating the risk of
ADRs, drug interactions and therapeutic errors, data analysis,
problems detection and planning for adequate training.
 Phase 2: we carried out multidisciplinary staff training with
nurses, general practitioners, specialist doctors, pharmacists
and created adequate operative tools
(“Do not crush list”, a specific handbook).
 Phase 3: included a second data collection and the analysis of
drug management, therapy and hospital admissions for
adverse events.
The analysis was conducted using 2 tools:
 Beers Criteria for potentially inappropriate medications.
 Micromedex 2.0 for drug interactions.
Phase 1 - Top Ten Drug Interactions
CLORPROMAZINA
QUETIAPINA
ACIDO
ACETILSALICILICO
SERTRALINA
ACIDO
ACETILSALICILICO
ENOXAPARINA
PANTOPRAZOLO
CITALOPRAM
METOCLOPRAMIDE
CLORPROMAZINA
LEVOFLOXACINA
QUETIAPINA
LEVOFLOXACINA
CLORPROMAZINA
ALOPERIDOLO
QUETIAPINA
METOCLOPRAMIDE
ALOPERIDOLO
METOCLOPRAMIDE
QUETIAPINA
These 10 drug interactions
represent 33% of all
interactions in the study
55% of patients in
the study had at
least 1 of these
interactions.
Beers Criteria
for Potentially Inappropriate Medication
Therapeutic category, Drug(s) Phase 1 Phase 3 Beers Warning
Digoxin 132 106 Avoid doses >0,125mg digoxin
Furosemide+Spironolactone 75 57 Avoid doses >25mg spironolactone
Doxazosin 38 32 Avoid as first line therapy
Antiarrhythmic drugs
(Amiodarone,Flecainide,
Propafenone, Sotalol)
67 62 Avoid as first line therapy
Proton Pump Inhibitors 750 704 Avoid use for > 8 weeks unless for
high risk patient
Benzodiazepines (Lorazepam,
Triazolan, Flurazepam)
667 651 Avoid for treatment of insomnia,
agitation or delirium
Phase 2 – Multiprofessional training (Nurses,
Pharmacists, GPs, Specialist doctors)
 Session 1: we discuss, clinical risk
management, therapeutic errors
 Session 2: we carry out, field training
and share procedures
 Session 3: we look at therapeutic
reconciliation, pharmacovigilance and
reduce polypharmacy
The practice of crushing medications
“Do not crush list”,
a specific handbook
Results (1)
Nursing home Reconciled meds N. of Interactions Crushing
1 -1,1 -29% -37%
2 +0,1 12% -3%
3 +0,04 -26% -6%
4 -0,5 41% -33%
5 +0,7 20% 8%
6 -0,2 -1% -7%
7 +0,02 8% 18%
8 +0,7 -1% 10%
9 -0,3 -33% -22%
10 -0,5 -23% 6%
11 -0,2 12% -28%
-0,1 -7% -9%
The interventions reduced the drug interactions by 7% and the
practice of crushing medication by 9%
Results (2)
N. of drugs 1-4 5-9 10+
Nursing Home 1 53% 43% 3%
Nursing Home 2 30% 58% 13%
Nursing Home 3 35% 52% 13%
Nursing Home 4 38% 53% 10%
Nursing Home 5 28% 62% 10%
Nursing Home 6 29% 58% 13%
Nursing Home 7 35% 54% 11%
Nursing Home 8 29% 59% 12%
Nursing Home 9 22% 65% 13%
Nursing Home 10 37% 57% 6%
Nursing Home 11 31% 56% 13%
34% 55% 11%
Phase 1 Phase 3
N. of drugs 1-4 5-9 10+
Nursing Home 1 32% 57% 11%
Nursing Home 2 29% 47% 24%
Nursing Home 3 34% 53% 13%
Nursing Home 4 32% 56% 13%
Nursing Home 5 36% 53% 10%
Nursing Home 6 22% 66% 12%
Nursing Home 7 44% 48% 8%
Nursing Home 8 38% 53% 9%
Nursing Home 9 15% 66% 19%
Nursing Home 10 35% 56% 9%
Nursing Home 11 26% 62% 12%
32% 56% 12%
The interventions reduced the proportion of patients in
therapy with more than 5 medications by 2%
Reduce and reconcile ....
... If we remove drugs, does it
worsen the state of patients’
health?
Results (3)
Pre
Intervention
(2013)
Post
Intervention
(2015)
95%
Confidence Interval
Admissions for ADRs 610 393
Hospital days 653,600 660,866
Rate post intervention 5.95 5.37 6.56
Rate pre intervention 9.33 8.61 10.10
Rate ratio 0.64 0.56 0.72
Rate difference -3.39 -4.33 -2.44
The hospital admissions for adverse events in nursing home
residents in the post intervention group were reduced by 36%.
The difference between the two rates is statistically significant.
Conclusions
 The study demonstrated how health personnel
training can impact upon medication management in
nursing homes.
 The most significant variations were evident in
facilities in which it was possible to modify nursing
and medical management in a multidisciplinary
approach.
 The best results occurred in those facilities where all
health professionals participated in the project and
worked together for improvement.
THANKS FOR
YOUR ATTENTION
Corrispondence to: rfalanga@tin.it
Conflict of interest: none

Polypharmacy in elderly patients:an intervention study in therapeutic management

  • 1.
    POLYPHARMACY IN ELDERLYPATIENTS: AN INTERVENTION STUDY IN THERAPEUTIC MANAGEMENT Rosario Falanga¹, G. Pessa¹, B. Basso², A. Bertoli², A. Franzo², D. Little², G. Simon² ¹General Practitioner, SIMG, Pordenone, Italy, ²Azienda per l’Assistenza Sanitaria n.5 “Friuli Occidentale”, Pordenone, Italy
  • 2.
    Background  The increasein average life expectancy has over time resulted in a rising incidence of chronic degenerative diseases and consequent polypharmacy in older adults, with an augmented risk of Adverse Drug Reactions (ADRs) and Potentially Inappropriate Drug Prescriptions (PIDP).  Older people are medically frail because of age- related pharmacokinetic and pharmacodynamic changes.  Deprescribing will reduce the risk of adverse drug reactions due to age-related physiological changes and inappropriate prescriptions.
  • 3.
    PERCENTAGE OF REPORTSWITH POTENTIAL DRUG-DRUG INTERACTIONS IN RELATION TO THE NUMBER OF DRUGS IDENTIFYING ADVERSE DRUG REACTIONS ASSOCIATED WITH DRUG-DRUG INTERACTIONS DATA OF A SPONTANEOUS REPORTING DATABASE IN ITALY (Leone R., Drug Saf 2010)
  • 4.
    Ippocrate (460 -335 B.C.) “PRIMUM NON NOCERE” (First, do not harm)
  • 6.
    Polypharmacy in elderlypatients: an intervention study in therapeutic management  Pharmacovigilance project financed by the Italian Medicines Agency (AIFA).  Participating Organisations and Facilities:  AAS5 “Agency for Public Health Service n.5 Western Friuli” (Office of the Medical Director, Internal Medicine Department, Pharmacy Department, Territorial Health Districts, Dept. of Mental Health, Nursing Services)  General Practitioners (SIMG, Pordenone)  Nursing homes in the Province of Pordenone
  • 7.
    Objectives  We conducteda qualitative and quantitative analysis of polypharmacy in elderly patients, in therapy with multiple prescription medicines evaluating the risk of ADRs, drug interactions and therapeutic errors before and after adequate staff training aimed at reducing the number of administered drugs and ADRs in this population.
  • 8.
    Methods (1) A cohortof 750 elderly patients living in 11 nursing homes, in the province of Pordenone in northern Italy, average age 85 (65-103), 81% females, were enrolled in the study, which lasted for 3 years (2013-2015) and included 3 phases. Age Phase 1 n.1123 Phase 2 Training Phase 3 n.1112 Present Both phases n.750 Min. 65 65 65 Max 106 103 103 Media 86 85 85 Female% 79 79 81
  • 9.
    Methods (2)  Phase1: included medical record audit, data collection of drug therapy and drug management, evaluating the risk of ADRs, drug interactions and therapeutic errors, data analysis, problems detection and planning for adequate training.  Phase 2: we carried out multidisciplinary staff training with nurses, general practitioners, specialist doctors, pharmacists and created adequate operative tools (“Do not crush list”, a specific handbook).  Phase 3: included a second data collection and the analysis of drug management, therapy and hospital admissions for adverse events. The analysis was conducted using 2 tools:  Beers Criteria for potentially inappropriate medications.  Micromedex 2.0 for drug interactions.
  • 10.
    Phase 1 -Top Ten Drug Interactions CLORPROMAZINA QUETIAPINA ACIDO ACETILSALICILICO SERTRALINA ACIDO ACETILSALICILICO ENOXAPARINA PANTOPRAZOLO CITALOPRAM METOCLOPRAMIDE CLORPROMAZINA LEVOFLOXACINA QUETIAPINA LEVOFLOXACINA CLORPROMAZINA ALOPERIDOLO QUETIAPINA METOCLOPRAMIDE ALOPERIDOLO METOCLOPRAMIDE QUETIAPINA These 10 drug interactions represent 33% of all interactions in the study 55% of patients in the study had at least 1 of these interactions.
  • 11.
    Beers Criteria for PotentiallyInappropriate Medication Therapeutic category, Drug(s) Phase 1 Phase 3 Beers Warning Digoxin 132 106 Avoid doses >0,125mg digoxin Furosemide+Spironolactone 75 57 Avoid doses >25mg spironolactone Doxazosin 38 32 Avoid as first line therapy Antiarrhythmic drugs (Amiodarone,Flecainide, Propafenone, Sotalol) 67 62 Avoid as first line therapy Proton Pump Inhibitors 750 704 Avoid use for > 8 weeks unless for high risk patient Benzodiazepines (Lorazepam, Triazolan, Flurazepam) 667 651 Avoid for treatment of insomnia, agitation or delirium
  • 12.
    Phase 2 –Multiprofessional training (Nurses, Pharmacists, GPs, Specialist doctors)  Session 1: we discuss, clinical risk management, therapeutic errors  Session 2: we carry out, field training and share procedures  Session 3: we look at therapeutic reconciliation, pharmacovigilance and reduce polypharmacy
  • 13.
    The practice ofcrushing medications
  • 14.
    “Do not crushlist”, a specific handbook
  • 15.
    Results (1) Nursing homeReconciled meds N. of Interactions Crushing 1 -1,1 -29% -37% 2 +0,1 12% -3% 3 +0,04 -26% -6% 4 -0,5 41% -33% 5 +0,7 20% 8% 6 -0,2 -1% -7% 7 +0,02 8% 18% 8 +0,7 -1% 10% 9 -0,3 -33% -22% 10 -0,5 -23% 6% 11 -0,2 12% -28% -0,1 -7% -9% The interventions reduced the drug interactions by 7% and the practice of crushing medication by 9%
  • 16.
    Results (2) N. ofdrugs 1-4 5-9 10+ Nursing Home 1 53% 43% 3% Nursing Home 2 30% 58% 13% Nursing Home 3 35% 52% 13% Nursing Home 4 38% 53% 10% Nursing Home 5 28% 62% 10% Nursing Home 6 29% 58% 13% Nursing Home 7 35% 54% 11% Nursing Home 8 29% 59% 12% Nursing Home 9 22% 65% 13% Nursing Home 10 37% 57% 6% Nursing Home 11 31% 56% 13% 34% 55% 11% Phase 1 Phase 3 N. of drugs 1-4 5-9 10+ Nursing Home 1 32% 57% 11% Nursing Home 2 29% 47% 24% Nursing Home 3 34% 53% 13% Nursing Home 4 32% 56% 13% Nursing Home 5 36% 53% 10% Nursing Home 6 22% 66% 12% Nursing Home 7 44% 48% 8% Nursing Home 8 38% 53% 9% Nursing Home 9 15% 66% 19% Nursing Home 10 35% 56% 9% Nursing Home 11 26% 62% 12% 32% 56% 12% The interventions reduced the proportion of patients in therapy with more than 5 medications by 2%
  • 17.
    Reduce and reconcile.... ... If we remove drugs, does it worsen the state of patients’ health?
  • 18.
    Results (3) Pre Intervention (2013) Post Intervention (2015) 95% Confidence Interval Admissionsfor ADRs 610 393 Hospital days 653,600 660,866 Rate post intervention 5.95 5.37 6.56 Rate pre intervention 9.33 8.61 10.10 Rate ratio 0.64 0.56 0.72 Rate difference -3.39 -4.33 -2.44 The hospital admissions for adverse events in nursing home residents in the post intervention group were reduced by 36%. The difference between the two rates is statistically significant.
  • 19.
    Conclusions  The studydemonstrated how health personnel training can impact upon medication management in nursing homes.  The most significant variations were evident in facilities in which it was possible to modify nursing and medical management in a multidisciplinary approach.  The best results occurred in those facilities where all health professionals participated in the project and worked together for improvement.
  • 20.
    THANKS FOR YOUR ATTENTION Corrispondenceto: rfalanga@tin.it Conflict of interest: none